Cardiogenic shock complicating acute myocardial infarction in the elderly: Predictors of long-term survival

2011 ◽  
Vol 78 (4) ◽  
pp. 505-511 ◽  
Author(s):  
Francesco Tomassini ◽  
Andrea Gagnor ◽  
Alessandro Migliardi ◽  
Emanuele Tizzani ◽  
Vincenzo Infantino ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Cardiogenic Shock ◽  
The Elderly ◽  
Term Survival ◽  
Long Term Survival

scholarly journals Long-Term Survival and Outcomes After Hospitalization for Acute Myocardial Infarction Complicated by Cardiogenic Shock

2009 ◽  
Vol 32 (8) ◽  
pp. E4-E8 ◽  
Author(s):  
Stavros G. Drakos ◽  
Michael J. Bonios ◽  
Maria I. Anastasiou-Nana ◽  
Eleftheria P. Tsagalou ◽  
John V. Terrovitis ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Cardiogenic Shock ◽  
Term Survival ◽  
Long Term Survival

scholarly journals 901-35 Has Long-term Survival Improved for the Elderly with Acute Myocardial Infarction?

1995 ◽  
Vol 25 (2) ◽  
pp. 13A
Author(s):  
Hiroyuki Daida ◽  
Thomas E. Kottke ◽  
Richard J. Backes ◽  
Eric G. Tangalos ◽  
Kent R. Bailey
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
The Elderly ◽  
Term Survival ◽  
Long Term Survival

Early Impella Support in Postcardiac Arrest Cardiogenic Shock Complicating Acute Myocardial Infarction Improves Short- and Long-Term Survival

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Georgios Chatzis ◽  
Birgit Markus ◽  
Ulrich Luesebrink ◽  
Holger Ahrens ◽  
Dimitar Divchev ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Cardiogenic Shock ◽  
Term Survival ◽  
Long Term Survival ◽  
Short And Long Term

scholarly journals Early Revascularization and Long-term Survival in Cardiogenic Shock Complicating Acute Myocardial Infarction

JAMA ◽  
2006 ◽  
Vol 295 (21) ◽  
pp. 2511 ◽  
Author(s):  
Judith S. Hochman ◽  
Lynn A. Sleeper ◽  
John G. Webb ◽  
Vladimir Dzavik ◽  
Christopher E. Buller ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Cardiogenic Shock ◽  
Term Survival ◽  
Long Term Survival ◽  
Early Revascularization

scholarly journals Long-term survival benefit of ramipril in patients with acute myocardial infarction complicated by heart failure

Heart ◽  
2021 ◽  
Vol 107 (5) ◽  
pp. 389-395
Author(s):  
Jianhua Wu ◽  
Alistair S Hall ◽  
Chris P Gale
Keyword(s):  
Myocardial Infarction ◽  
Heart Failure ◽  
Acute Myocardial Infarction ◽  
Life Expectancy ◽  
Survival Benefit ◽  
Ace Inhibition ◽  
Survival Times ◽  
Term Survival ◽  
Long Term Survival

AimsACE inhibition reduces mortality and morbidity in patients with heart failure after acute myocardial infarction (AMI). However, there are limited randomised data about the long-term survival benefits of ACE inhibition in this population.MethodsIn 1993, the Acute Infarction Ramipril Efficacy (AIRE) study randomly allocated patients with AMI and clinical heart failure to ramipril or placebo. The duration of masked trial therapy in the UK cohort (603 patients, mean age=64.7 years, 455 male patients) was 12.4 and 13.4 months for ramipril (n=302) and placebo (n=301), respectively. We estimated life expectancy and extensions of life (difference in median survival times) according to duration of follow-up (range 0–29.6 years).ResultsBy 9 April 2019, death from all causes occurred in 266 (88.4%) patients in placebo arm and 275 (91.1%) patients in ramipril arm. The extension of life between ramipril and placebo groups was 14.5 months (95% CI 13.2 to 15.8). Ramipril increased life expectancy more for patients with than without diabetes (life expectancy difference 32.1 vs 5.0 months), previous AMI (20.1 vs 4.9 months), previous heart failure (19.5 vs 4.9 months), hypertension (16.6 vs 8.3 months), angina (16.2 vs 5.0 months) and age >65 years (11.3 vs 5.7 months). Given potential treatment switching, the true absolute treatment effect could be underestimated by 28%.ConclusionFor patients with clinically defined heart failure following AMI, ramipril results in a sustained survival benefit, and is associated with an extension of life of up to 14.5 months for, on average, 13 months treatment duration.

Sign in / Sign up

Export Citation Format

Share Document